Immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) announced on Thursday that it has received approval from the European Commission for subcutaneous injectable VYVGART (efgartigimod alfa) as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
The EC previously approved VYVGART for intravenous (IV) use in August 2022.
This latest decision follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) and was based on positive results from the Phase 3 ADAPT-SC study.
The approval applies to all 27 European Union Member States plus Iceland, Norway and Liechtenstein.
VYVGART SC, a subcutaneous injectable formulation of efgartigimod alfa, incorporates Halozyme's ENHANZE drug delivery technology to facilitate SC injection delivery of biologics. By binding to the neonatal Fc receptor (FcRn), VYVGART leads to a reduction in circulating IgG autoantibodies.
Pierre Fabre Pharmaceuticals reports FDA acceptance and Priority Review of Tabelecleucel BLA
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
Atara Biotherapeutics gains FDA Priority Review for tabelecleucel
Hyperfine secures FDA clearance for faster brain imaging software
Silo Pharma agrees Alzheimer's drug licence
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation
Camurus reports positive Phase 3 ACROINNOVA 2 results
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI